Pranav Patel

Founder & CEO

India's pharmaceutical formulation manufacturing sector is a global powerhouse that produces over 60,000 generic brands across 60 therapeutic categories and supplies 20 percent of the world's generic medicines by volume. With over 3,000 companies, 10,500 manufacturing facilities, and the highest number of USFDA-compliant plants outside the U.S., India is a key supplier to more than 200 countries. However, the sector faces challenges such as fluctuating raw material prices due to dependence on China for APIs, stringent regulatory requirements, and increasing global competition. Despite these hurdles, government initiatives such as the Production Linked Incentive (PLI) scheme and investments in biopharmaceuticals, specialty drugs, and automation are driving growth in delivering high-quality, cost-effective medicines globally.

Established in 2009, Exemed Pharmaceuticals has emerged as a prominent player in the manufacturing of Active Pharmaceutical Ingredients (APIs) and offering formulation contract manufacturing services. The company upholds the highest standards of quality and compliance with approvals from major regulatory authorities, including the USFDA and EUGMP. It operates two advanced manufacturing facilities including an API facility in Vadodara, Gujarat, catering to stringent USFDA regulations, and a formulation plant in Vapi, Gujarat, certified by EUGMP for producing tablets and capsules. With a focus on niche and orphan products, Exemed Pharmaceuticals has established its presence in key global markets, such as Central America, East Asia, Europe, and the Middle East. In addition, the company has secured approvals for several fixed-dose combination (FDC) products from India’s CDSCO.

Exemed Pharmaceuticals sets itself apart in the pharmaceutical industry through its efficiency, quality standards, and customer-focused approach. One of its key strengths is the ability to secure rapid regulatory approvals, allowing for a quicker market entry while maintaining transparency with stakeholders. The company prioritizes customer satisfaction by offering cost-effective, high-quality solutions and swiftly addressing concerns. Its adaptability enables it to expand production capacity and develop specialized formulations to meet evolving market needs.

Sustainability, Safety, & Quality
Exemed Pharmaceuticals integrates energy-efficient technologies, minimizes waste, and adopts eco-friendly manufacturing practices to reduce its environmental impact. A key step in this direction is its solar energy joint venture with Torrent which significantly lowers its carbon footprint. “We have reinforced Ecovadis and ISO certifications, in compliance with stringent environmental and social responsibility standards. Workplace safety is a top priority, with regular training programs and stringent protocols ensuring a secure and health-conscious environment for employees”, asserts Pranav Patel, Founder & CEO, Exemed Pharmaceuticals. 

On the quality front, Exemed Pharmaceuticals strictly adheres to global regulatory standards, including USFDA and EU GMP, implementing rigorous testing and continuous monitoring throughout production. These initiatives collectively enable the company to manufacture high-quality, cost-effective medicines while maintaining environmental responsibility and prioritizing human health and safety.

Harnessing Innovation & Expertise
Exemed Pharmaceuticals stays ahead in the industry by combining advanced technology with a highly skilled workforce. Its state-of-the-art manufacturing facilities incorporate automation, real-time monitoring, and data analytics to enhance efficiency and ensure stringent quality control. Research and development drive the creation of innovative formulations and the improvement of existing products.

Continuous employee training keeps its team at the forefront of industry advancements, fostering innovation and precision. Exemed Pharmaceuticals optimizes processes while maintaining strict regulatory compliance by integrating cutting-edge techniques in drug discovery and manufacturing. This allows the company to adapt to evolving healthcare needs while maintaining excellence in production, innovation, and compliance. 

Customer Satisfaction & Continuous Improvement
Exemed Pharmaceuticals places customer satisfaction at the core of its operations by implementing a structured approach to address feedback and enhance service quality. “A dedicated team actively manages customer queries, complaints, and suggestions, ensuring swift resolution and a seamless experience. We gather valuable insights to identify areas for improvement and consistently meet customer expectations through multiple communication channels”, adds Pranav.

Transparent communication is a priority, with regular updates provided throughout the resolution process to foster trust and reliability. In cases involving product quality, Exemed Pharmaceuticals follows a thorough investigation and corrective action process to prevent recurrence. The company takes a proactive approach by anticipating potential concerns and addressing them before they escalate. This customer-centric strategy has played a key role in its rapid expansion and helped secure partnerships with major Indian pharmaceutical companies.

The Way Ahead
The pharmaceutical industry is poised for significant growth, driven by rising healthcare demands and advancements in medical research. One of the fastest-growing segments is oncology, as cancer remains a leading cause of mortality worldwide. The global oncology market is projected to surpass $500 billion by 2030, driven by increasing cancer incidence, advancements in precision medicine, and a growing demand for affordable yet effective treatments. Recognizing this need, Exemed Pharmaceuticals is making strategic investments in oncology drug manufacturing to contribute to affordable, high-quality cancer treatment solutions. The company is developing a state-of-the-art oncology facility at its Vapi site, designed to meet stringent international regulatory standards, including EU GMP certification. This initiative will enable it to manufacture high-quality cancer treatment formulations and strengthen its foothold in the growing oncology market. The company is also expanding its product portfolio to include cardiovascular and generic medicines to ensure a diverse range of solutions.

The company will also make investments in advanced Formulation Development (F&D) and Research and Development (R&D) facilities to drive the creation of novel formulations. “We are also developing a specialized plant for regulated market formulations, targeting the U.S. and European markets. We are set to maintain our competitive edge and drive long-term industry leadership by securing international certifications, adopting cutting-edge technologies, and enhancing global reach”, concludes Pranav.